November 1, 2023
Sumitomo Pharma President Hiroshi Nomura Sumitomo Pharma aims to swing back to profitability on a core basis in FY2024 after the US patent expiry of Latuda (lurasidone) sent the company plunging into an operating loss in the first half of...read more